Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Mechanisms of MYC stabilization in human malignancies.
Junttila MR, Westermarck J. Junttila MR, et al. Cell Cycle. 2008 Mar 1;7(5):592-6. doi: 10.4161/cc.7.5.5492. Epub 2007 Dec 29. Cell Cycle. 2008. PMID: 18256542 Review.
BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues.
Muthalagu N, Junttila MR, Wiese KE, Wolf E, Morton J, Bauer B, Evan GI, Eilers M, Murphy DJ. Muthalagu N, et al. Cell Rep. 2014 Sep 11;8(5):1347-53. doi: 10.1016/j.celrep.2014.07.057. Epub 2014 Aug 28. Cell Rep. 2014. PMID: 25176652 Free PMC article.
Selective activation of p53-mediated tumour suppression in high-grade tumours.
Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP. Junttila MR, et al. Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526. Nature. 2010. PMID: 21107427 Free PMC article.
Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation.
Finch AJ, Soucek L, Junttila MR, Swigart LB, Evan GI. Finch AJ, et al. Mol Cell Biol. 2009 Oct;29(19):5306-15. doi: 10.1128/MCB.01745-08. Epub 2009 Jul 27. Mol Cell Biol. 2009. PMID: 19635809 Free PMC article.
p53--a Jack of all trades but master of none.
Junttila MR, Evan GI. Junttila MR, et al. Nat Rev Cancer. 2009 Nov;9(11):821-9. doi: 10.1038/nrc2728. Epub 2009 Sep 24. Nat Rev Cancer. 2009. PMID: 19776747 Review.
MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.
Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimäki A. Khanna A, et al. J Natl Cancer Inst. 2009 Jun 3;101(11):793-805. doi: 10.1093/jnci/djp103. Epub 2009 May 26. J Natl Cancer Inst. 2009. PMID: 19470954
Distinct thresholds govern Myc's biological output in vivo.
Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. Murphy DJ, et al. Cancer Cell. 2008 Dec 9;14(6):447-57. doi: 10.1016/j.ccr.2008.10.018. Cancer Cell. 2008. PMID: 19061836 Free PMC article.
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Junttila MR, Devasthali V, Cheng JH, Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan H, Cao T, Forrest W, Nannini MA, French D, Carano R, Merchant M, Hoeflich KP, Singh M. Junttila MR, et al. Mol Cancer Ther. 2015 Jan;14(1):40-7. doi: 10.1158/1535-7163.MCT-14-0030. Epub 2014 Nov 5. Mol Cancer Ther. 2015. PMID: 25376606
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.
Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A, Tan M, Meng YG, Jackson EL, Peale FV, Junttila MR, Ferrara N. Phan VT, et al. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6079-84. doi: 10.1073/pnas.1303302110. Epub 2013 Mar 25. Proc Natl Acad Sci U S A. 2013. PMID: 23530240 Free PMC article.
Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Croci DO, et al. Cell. 2014 Feb 13;156(4):744-58. doi: 10.1016/j.cell.2014.01.043. Cell. 2014. PMID: 24529377
39 results
Jump to page